Skip to main content
. 2022 Jan 1;12(1):362–378. doi: 10.7150/thno.65597

Figure 2.

Figure 2

Sonobiopsy increased the sensitivity of EGFRvIII and TERT C228T mutation detections in mouse plasma by ddPCR. (A) 1D amplitude plots for blood LBx and sonobiopsy groups demonstrate the detection of EGFRvIII in plasma for each representative subject. The pink line depicts the threshold fluorescence for identifying droplets with positive EGFRvIII expression. (B) The level in the sonobiopsy group (n = 17; 19.06 ± 24.74 copies/µL) was significantly greater (p = 0.00089; ***p < 0.001; unpaired two-sample Wilcoxon signed rank test) compared with the level in the blood LBx group (n = 14; 0.02 ± 0.08 copies/µL). (C) 1D amplitude plots for the detection of TERT C228T in plasma for each representative subject in the blood LBx and sonobiopsy groups. The pink line depicts the threshold fluorescence for identifying droplets with positive TERT C228T expression. (D) FUS significantly increased the levels of TERT C228T ctDNA in the plasma from 0.06 ± 0.18 copies/µL in the blood LBx group (n = 21) to 0.64 ± 1.19 copies/µL in the sonobiopsy group (n = 24; p = 0.015; *p < 0.01; unpaired two-sample Wilcoxon signed rank test). (E) With ddPCR, sonobiopsy is more sensitive than blood LBx with a detection rate of 64.71% for EGFRvIII and 45.83% for TERT C228T compared with 7.14% and 14.29% for blood LBx, respectively. ND: not detected. Black bars indicate mean in B and D.